211P ER-low breast cancer: Evolution from primary tumor to relapse and prognostic impact
Federica Miglietta(University of Padua), Maria Vittoria Dieci(Istituto Oncologico Veneto), Fabio Girardi(London School of Hygiene & Tropical Medicine), Grazia Maria Vernaci(University of Padua), V. Guarneri(University of Padua), Rocco Cappellesso(University of Padua), Francesca Porra(University of Padua), Matteo Fassan(University of Padua), Tommaso Giarratano(Istituto Oncologico Veneto), Michele Bottosso(University of Padua), Carlo Alberto Giorgi(Istituto Oncologico Veneto), Gaia Griguolo(University of North Carolina at Chapel Hill), M. Cacciatore(AULSS 2 Marca Trevigiana), C. Zurlo(University of Padua), A Crema(University of Padua), Daniela Iannaccone(University of Padua)
Cited by 1
Related Papers
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
|Nature Genetics|2013|709
Sustainable care for children with cancer: a Lancet Oncology Commission
|The Lancet Oncology|2020|346
Evolution of HER2-low expression from primary to recurrent breast cancer
|npj Breast Cancer|2021|226
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
|JNCI Journal of the National Cancer Institute|2019|168